Melanoma treated with curative immunotherapy (IPILIMUMAB + NIVOLUMAB or NIVOLUMAB or PEMBROLIZUMAB or NIVOLUMAB + RELATLIMAB) or adjuvant immunotherapy (NIVOLUMAB or PEMBROLIZUMAB)
Patients monitored and treated at the dermatology day hospital at Grenoble Alpes University Hospital
Obtaining the patient's consent
Start of immunotherapy less than or equal to 1 year at the time of inclusion
Subject affiliated with social security system
You may not be if
Recurrence of the disease within 6 months or less after a first line of adjuvant treatment with immunotherapy for 1 year
Immunotherapy as a third line of treatment in metastatic situations
Squamous cell carcinoma or basal cell carcinoma treated with immunotherapy
Inability to complete the FiberTAG and GPAQ questionnaires (advanced neurocognitive disorders, memory loss, etc.)
Inclusion in an interventional clinical study
Immunotherapy in a neoadjuvant situation
Persons referred to in Articles L1121-5 to L1121-8 of the CSP (corresponds to all protected persons: pregnant women, women in labor, breastfeeding mothers, persons receiving psychiatric care under Articles L. 3212-1 and L. 3213-1 who are not covered by the provisions of Article L. 1121-8, persons admitted to a health or social care institution for purposes other than research, minors, persons subject to legal protection measures or unable to give their consent). persons subject to legal protection measures)
Clareo Health | Influence of a High-fiber Diet on the Microbiota and the Response to Immunotherapy in Patients Treated for Melanoma.
